NCT03603977 Simplified Treatment of Anti-retrovirus in China (C-STAR)
| NCT ID | NCT03603977 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Guangzhou 8th People's Hospital |
| Condition | HIV/AIDS |
| Study Type | OBSERVATIONAL |
| Enrollment | 600 participants |
| Start Date | 2017-11-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 600 participants in total. It began in 2017-11-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.
Eligibility Criteria
Inclusion Criteria: 1. HIV-1 infection confirmed 2. Agree to use simplified therapy regimen. 3. Agree to detect CD4 count at least once per half a year Exclusion Criteria: 1. Have participated in HIV vaccine clinical trial or other drug trials in the past three months. 2. Patients who could not complete the scheduled follow-up (such as weakness and poor compliance). 3. Patients who have the history of resistance or allergy to LPV/r or 3TC.
Contact & Investigator
Weiping Cai, Bachelor
STUDY CHAIR
Guangzhou 8th People's Hospital
Frequently Asked Questions
Who can join the NCT03603977 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV/AIDS. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03603977 currently recruiting?
Yes, NCT03603977 is actively recruiting participants. Contact the research team at llheliza@126.com for enrollment information.
Where is the NCT03603977 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT03603977 clinical trial?
NCT03603977 is sponsored by Guangzhou 8th People's Hospital. The principal investigator is Weiping Cai, Bachelor at Guangzhou 8th People's Hospital. The trial plans to enroll 600 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.